Press releases

17 April, 2014

Regulatory

NeuroVive presents medical breakthrough in cellular energy regulation

NeuroVive, a leading mitochondrial medicine company, is presenting a breakthrough in the company's work on energy regulation at the cellular level. Based on the UK company Selcia Ltd's medical chemist ...

17 April, 2014

Regulatory

NeuroVive Pharmaceutical’s 2013 Annual Report now available

Today, NeuroVive Pharmaceutical AB (publ) announced that the Annual Report for 2013 is available as PDF at www.neurovive.com, and can be read via the link below. The available report is in Swedish. An ...

10 April, 2014

Regulatory

NeuroVive Stock Now Trading in the USA on the OTC Market

NeuroVive Pharmaceutical AB stock shares were registered with the OTC Reporting Facility for Foreign shares in New York City with the ticker symbol NEVPF:US on March 20, 2014. NeuroVive trades on the ...

9 April, 2014

Regulatory

Invitation to the AGM of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting (AGM) of shareholders at 3 p.m. on Friday, 9 May 2014 a ...

31 March, 2014

Regulatory

Increased individual ownership through share exchange from Maas Biolab, LLC

One of NeuroVive's largest shareholders, Maas Biolab, LLC is reducing its ownership by 359,304 shares through a share exchange with its Swedish and US shareholders. This share exchange involves Maas B ...

31 March, 2014

Regulatory

NeuroVive Pharmaceutical AB—amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issues conducted by NeuroVive Pharmaceutical AB (p ...

28 March, 2014

Regulatory

NeuroVive presents significant hepatitis B data for its drug candidate NVP018

NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to c ...

25 March, 2014

Regulatory

NeuroVive Pharmaceutical and A1M Pharma initiate research collaboration

NeuroVive Pharmaceutical AB (publ) and A1M Pharma AB (publ) have announced that the two companies are initiating a research collaboration in mitochondrial medicine. The partnership is governed by a co ...

13 March, 2014

Regulatory

NeuroVive Pharmaceutical AB—amendment number of shares and votes

As a result of new share issues conducted by NeuroVive Pharmaceutical AB (publ) ("NeuroVive"), as resolved by an Extraordinary General Meeting (EGM) on 13 December 2013, and decided by the Board of Di ...

10 March, 2014

Regulatory

NeuroVive starts collaboration to evaluate IPO of subsidiary in Taiwan

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is reporting that the company's subsidiary NeuroVive Pharmaceutical Asia Ltd., whose registered office is in Hong Kong, ha ...

19 February, 2014

Regulatory

NeuroVive: Year-End Report 1 Jan. 2013 till 31 Dec. 2013

NeuroVive consolidates positioning as leading mitochondrial medicine company

17 February, 2014

Regulatory

NeuroVive treats final patient in European phase III trial on CicloMulsion®

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has reported that the last of a total of 972 patients have now been enrolled and treated in its ongoing European phase III ...